Dyslipidemia is a chronic disease characterized by elevated blood lipid levels treatable with statins. However, long-term statin use may have adverse effects, such as liver damage and memory loss. Nevertheless, plants and their active compounds effectively and safely improve lipid profiles. This review aims to update information on the genus Berberis as a hypolipidemic agent, assess the effects of these extracts on organisms and provide evidence supporting the use of these natural products in pharmaceutical drugs. Berberis species with therapeutic potential include B. vulgaris, B. integerrima, B. aristata, B. lycium, B. orthobotrys, and B. calliobotrys, which have shown promising results in reducing lipid levels in humans and other animals. In addition, combining berberine with nutraceuticals may improve its intestinal absorption, enhancing its lipid-lowering effect. Herbal medicine studies suggest that Berberis has a high potential for the management of hyperlipidemia.